Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus

por Hoshika, Yu, Kubota, Yoshiaki, Mozawa, Kosuke, Tara, Shuhei, Tokita, Yukichi, Yodogawa, Kenji, Iwasaki, Yu-ki, Yamamoto, Takeshi, Takano, Hitoshi, Tsukada, Yayoi, Asai, Kuniya, Miyamoto, Masaaki, Miyauchi, Yasushi, Kodani, Eitaro, Maruyama, Mitsunori, Tanabe, Jun, Shimizu, Wataru
Publicado 2021

Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus

por Mozawa, Kosuke, Kubota, Yoshiaki, Hoshika, Yu, Tara, Shuhei, Tokita, Yukichi, Yodogawa, Kenji, Iwasaki, Yu‐ki, Yamamoto, Takeshi, Takano, Hitoshi, Tsukada, Yayoi, Asai, Kuniya, Miyamoto, Masaaki, Miyauchi, Yasushi, Kodani, Eitaro, Maruyama, Mitsunori, Tanabe, Jun, Shimizu, Wataru
Publicado 2021

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial

por Shimizu, Wataru, Kubota, Yoshiaki, Hoshika, Yu, Mozawa, Kosuke, Tara, Shuhei, Tokita, Yukichi, Yodogawa, Kenji, Iwasaki, Yu-ki, Yamamoto, Takeshi, Takano, Hitoshi, Tsukada, Yayoi, Asai, Kuniya, Miyamoto, Masaaki, Miyauchi, Yasushi, Kodani, Eitaro, Ishikawa, Masahiro, Maruyama, Mitsunori, Ogano, Michio, Tanabe, Jun
Publicado 2020